Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Open-label Maintenance Treatment with Oral OPC-34712 in Adults with Schizophrenia
2011-002514-37Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brexpiprazole in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Safety and tolerability of OPC-34712. Started Aug 2011; status: completed.
02
Drugs
brexpiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2011-002514-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002514-37.